BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Analysts Set New Price Targets
BIOL has been the subject of several recent research reports. Lake Street Capital initiated coverage on shares of BIOLASE in a research report on Friday, May 20th. They issued a "buy" rating and a $12.00 price objective for the company. StockNews.com initiated coverage on shares of BIOLASE in a research report on Friday. They issued a "sell" rating for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, BIOLASE currently has an average rating of "Moderate Buy" and an average price target of $41.50.
BIOLASE Stock Performance
BIOL traded down $0.44 during trading hours on Tuesday, reaching $5.05. 36 shares of the stock traded hands, compared to its average volume of 29,712. The firm's fifty day simple moving average is $4.52 and its two-hundred day simple moving average is $7.34. BIOLASE has a fifty-two week low of $3.30 and a fifty-two week high of $23.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.34 and a quick ratio of 2.22.
BIOLASE (NASDAQ:BIOL - Get Rating) last released its quarterly earnings results on Thursday, May 12th. The medical technology company reported ($0.81) earnings per share for the quarter. BIOLASE had a negative net margin of 34.03% and a negative return on equity of 62.40%. The firm had revenue of $10.17 million for the quarter.